3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
45
Neoplasm Metastasis
5
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms, Castration-Resistant
2
Ovarian Neoplasms
2
Metastatic Castration-Resistant Prostate Cancer
2
Melanoma
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Bulbo-Spinal Atrophy, X-Linked
2
Bites and Stings
2
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Salivary Gland Neoplasms
1
Prostate Cancer Metastatic Disease
1
Prostate Adenocarcinoma
1
Primary Myelofibrosis
1
Pancreatic Neoplasms
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Newly Diagnosed Oligometastatic Prostate Cancer
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Hormone-Sensitive Prostate Cance
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Non-Hodgkin
1
Interventions
Oxaliplatin
19
pembrolizumab
13
Fluorouracil
12
Leucovorin
11
Capecitabine
11
Paclitaxel
10
Gemcitabine
8
Docetaxel
8
zolbetuximab
6
cemiplimab
6
Cisplatin
6
Albumin-Bound Paclitaxel
6
durvalumab
5
Ramucirumab
5
Radiotherapy
5
Irinotecan
4
Cyclophosphamide
4
130-nm albumin-bound paclitaxel
4
trastuzumab deruxtecan
3
tislelizumab
3
lenvatinib
3
enzalutamide
3
darolutamide
3
Trastuzumab
3
Taxes
3
S 1 (combination)
3
Radiosurgery
3
Pemetrexed
3
Nivolumab
3
Carboplatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
abiraterone
×
1 year
×
Clear all
NCT06592924
2026-04-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3
Recruiting
830 enrolled